# High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

> **NCT06313502** · PHASE1 · RECRUITING · sponsor: **University of Arkansas** · enrollment: 18 (estimated)

## Conditions studied

- Plasma Cell Disorder

## Interventions

- **DRUG:** 75gm HDAA
- **DRUG:** 100gm HDAA
- **DRUG:** 125gm HDAA

## Key facts

- **NCT ID:** NCT06313502
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-19
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313502, "High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06313502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*